



Recent Advances in Chimeric Antigen Receptor Technology

Guest Editor:

**Dr. Matthias Hardtke-
Wolenski**

Department of Gastroenterology,
Hepatology & Endocrinology,
Hannover Medical School, 30625
Hannover, Germany

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Immunotherapies play an increasingly important role as a therapeutic option for a broad spectrum of diseases, ranging from cancer to autoimmunity. The two main modulations can be summarized by antibody therapies or adoptive cell transfer. Here, the idea of using chimeric antigen receptors (CARs) to produce modified cells is taking an increasingly important place. CARs recognize their antigen without the limitations of MHC II restriction.

Over the past decade, the continuous development of next-generation CARs has been outstanding. There are many options for CAR therapies. While the first trials started with cancer, autoimmunity was quickly added. Today, antifibrotic CAR therapies are also feasible. Additionally, the various possibilities in adapting CARs to their targets have been widely used. The target cells vary from T cells to regulatory T cells and natural killer cells.

In this Special Issue, we would like to collect recent publications on the research results and knowledge related to CAR technology.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)